Entera Bio financials
$2.690.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | $0.00 | $134.0K | $571.0K | $365.0K |
| Gross profit | $0.00 | $9.0K | $0.00 | $33.0K | $198.0K | $65.0K |
| Gross margin | 0.0% | 5.0% | — | 24.6% | 34.7% | 17.8% |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.3M | -$11.2M |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M | -$11.2M |
| Net margin | −27235.7% | −5271.3% | — | −9754.5% | −2134.3% | −3072.9% |
| Diluted EPS | $-0.25 | $-0.25 | $-0.31 | $-0.45 | $-0.47 | $-0.61 |
| EBITDA | -$11.5M | -$9.5M | -$8.9M | -$13.0M | -$12.2M | -$11.1M |
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| Free cash flow | -$7.5M | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| Diluted shares | 46.2M | 37.7M | 29.0M | 28.8M | 26.1M | 18.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.1M | $8.7M | $11.0M | $12.3M | $24.9M | $8.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $393.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M | $9.7M |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M | $2.2M |
| Shareholders' equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M | $7.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology